Herpes Zoster Infection Following Solid Organ Transplantation: Incidence, Risk Factors and Outcomes in the Current Immunosuppressive Era

American Journal of Transplantation

Volumn 4, Issue 1, 2004, Pages 108-115

  Gourishankar, Sita ^a   McDermid, Jill C ^a   Jhangri, Gian S ^a   Preiksaitis, Jutta K ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Herpes zoster; Infection; Transplantation

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALACICLOVIR;

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; HEART TRANSPLANTATION; HERPES VIRUS; HERPES ZOSTER; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LATENT VIRUS INFECTION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ORGAN TRANSPLANTATION; POSTHERPETIC NEURALGIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SCAR; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEART TRANSPLANTATION; HERPES ZOSTER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0742301293     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6143.2003.00287.x     Document Type: Article

References (28)

1. Schimpff S, Serpick A, Stoler B, Rumack B, Mellin H, Joseph JM, Block J. Varicella-zoster infection in patients with cancer. Ann Intern Med 1972; 76: 241-254.
2. Hope-Simpson RE. Post herpetic neuralgia. J R Coll General Pract 1975; 25: 571-575.
3. Kost RG, Strauss SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med 1996; 335: 32-42.
4. Gilden DH, Kreingschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complicatons of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342: 635-645.
5. Straus SE, Ostrove JM, Inchauspe G, Felser JM, Freifeld A, Croen KD, Sawyer MH. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108: 221-237.
6. Fehr T, Bossart W, Wahl C, Binswanger U. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. Transplant 2002; 73: 608-611.
7. st edn. Philadelphia: Lippincott-Raven, 1998: 265-286.
8. Hope-Simpson R. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9.
9. Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine 1982; 61: 310-316.
10. McGregor RM. Herpes zoster, chicken pox and cancer in general practice. BMJ 1957; 1: 84-87.
11. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605-1609.
12. Broyer M, Gagnadoux MF, Beurton D, Pascal B, Louville J. Transplantation in children: technical aspects, drug therapy and problems related to primary renal disease. Proc Eur Dial Transplant Assoc 1981; 18: 313-321.
13. Liesegang TJ. Varicella zoster viral disease. Mayo Clin Proc 1999; 74: 983-998.
14. Veenstra J, Krol A, van Praag RM et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995; 9: 1153-1158.
15. Alliegro MB, Dorrucci M, Pezzotti P et al. Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV seroconversion study. Clin Infect Dis 1996; 23: 990-995.
16. Hans CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277-283.
17. Steer CV, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657-664.
18. Hennekens CH, Buring JE. Measures of disease frequency. In: Mayrent SL (ed). Epidemiology in Medicine. Boston: Little, Brown and Company, 1987: 54-98.
19. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infections with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172-1181.
20. Atkinson K, Meyers JD, Storb R. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or infection or leukemia. Transplant 1980; 29: 47-50.
21. Schuchter LM, Wingard JR, Paintadosi S. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989; 74: 1424-1427.
22. Masaoka T, Hiraoka A, Teshima H, Tominaga N. Varicella-zoster virus infection in immunocompromised patients. J Med Virol 1993; 1: 82-84.
23. Lo CY, Cheng IK. Varicella-zoster infection in cyclosporine A-treated renal transplant patients. Transplant Proc 1996; 28: 1511-1512.
24. Rifkind D. The activation of varicella-zoster infections by immunosuppressive therapy. J Lab Clin Med 1966; 68: 474.
25. Gershon AA. Varicella vaccine: still at the crossroads. Pediatrics 1992; 90: 144-148.
26. Landow K. Acute and chronic herpes zoster. Postgrad Med 2000; 107: 107-118.
27. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26-34.
28. Fletcher CV, Englund JA, Edelman CK, Gross CR, Dunn DL, Balfour HH Jr. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 1991; 35: 938-943.